Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
40 hedge funds and large institutions have $6.42M invested in Viracta Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 14 closing their positions.
1,540% more call options, than puts
Call options by funds: $82K | Put options by funds: $5K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 48 → 40 (-8)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
81% less capital invested
Capital invested by funds: $33M → $6.42M (-$26.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$703K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$142K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$77.6K |
| 4 |
Morgan Stanley
New York
|
+$32.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$4.25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$802K |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$795K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$747K |
| 5 |
OH
Oikos Holdings
New York
|
-$365K |
VIRX Hedge Fund Activity: Q4 2018 in Review
40 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2018, worth a combined $6.42M — down 81% from $33M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VIRX and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was BVF Inc, adding an estimated $703K. The largest seller was Boxer Capital, exiting entirely with an estimated $4.25M sold.
- 40 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2018, down from 48 in Q3 2018.
- Funds reported $6.42M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2018, down 81% quarter-over-quarter.
- 6 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2018 and 14 closed out, a net change of -8 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2018 was BVF Inc, an estimated $703K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2018 was Boxer Capital, an estimated $4.25M sold.
Based on aggregated 13F filings for Q4 2018.